ILT-101 ld-(IL2) clinical trials

Use of Low Doses of Interleukin-2 in Autism Spectrum Disorders

This study is looking at a new treatment called ILT-101 for children aged 6 to 8 with autism. It aims to see if a low dose of this medicine can help improve autism symptoms by balancing certain immune cells, especially in children whose mothers had immune issues during pregnancy.